Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients

T lymphoblastic leukemia/lymphoma (T-ALL/LBL) is highly aggressive. Although intensive chemotherapies such as ALL-type regimens are commonly used, about half adult patients eventually relapse and die of T-ALL/LBL. Overwhelming evidences have confirmed that interim PET can predict survival outcomes a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Liang, Wang, Jing-Hua, Bi, Xi-Wen, Chen, Xiao-Qin, Lu, Yue, Xia, Zhong-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716796/
https://www.ncbi.nlm.nih.gov/pubmed/29228756
http://dx.doi.org/10.18632/oncotarget.19572
_version_ 1783284027327774720
author Wang, Liang
Wang, Jing-Hua
Bi, Xi-Wen
Chen, Xiao-Qin
Lu, Yue
Xia, Zhong-Jun
author_facet Wang, Liang
Wang, Jing-Hua
Bi, Xi-Wen
Chen, Xiao-Qin
Lu, Yue
Xia, Zhong-Jun
author_sort Wang, Liang
collection PubMed
description T lymphoblastic leukemia/lymphoma (T-ALL/LBL) is highly aggressive. Although intensive chemotherapies such as ALL-type regimens are commonly used, about half adult patients eventually relapse and die of T-ALL/LBL. Overwhelming evidences have confirmed that interim PET can predict survival outcomes and guide subsequent treatments in Hodgkin lymphoma. However, whether interim PET-CT can predict survival outcomes or not in T-ALL/LBL patients remains unclear. 47 adult patients of T-ALL/LBL were retrospectively reviewed. Interim PET-CT was done after induction therapy and evaluated according to the International Harmonization Project criteria. After induction therapy, interim PET-CT was positive in 19 patients (40.4%). After a median follow up time of 34 months, the 2-year and 3-year progression free survival (PFS) rate were 39% and 30%, respectively, and the 2-year and 3-year overall survival (OS) rate were 54% and 45%, respectively. Using Kaplan-Meier survival analysis, it was found that interim PET-CT positivity correlated with significantly inferior PFS and OS (2-year PFS rate for patients with positive or negative interim PET were 21.1% or 56.0%, respectively, p = 0.002; 2-year OS rate for patients with positive or negative interim PET were 31.6% or 63.7%, respectively, p = 0.010). However, there was no significant relationship between PFS, OS and bone marrow infiltration, lactate dehydrogenase level, and stages (p > 0.05). Interim PET-CT may predict PFS and OS in adult patients of T-ALL/LBL, which needs to be validated in prospective clinical trials. The optimal criteria for interim PET-CT evaluation and risk-adapted treatment strategy determined by interim PET-CT should be investigated in future clinical practice.
format Online
Article
Text
id pubmed-5716796
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57167962017-12-08 Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients Wang, Liang Wang, Jing-Hua Bi, Xi-Wen Chen, Xiao-Qin Lu, Yue Xia, Zhong-Jun Oncotarget Clinical Research Paper T lymphoblastic leukemia/lymphoma (T-ALL/LBL) is highly aggressive. Although intensive chemotherapies such as ALL-type regimens are commonly used, about half adult patients eventually relapse and die of T-ALL/LBL. Overwhelming evidences have confirmed that interim PET can predict survival outcomes and guide subsequent treatments in Hodgkin lymphoma. However, whether interim PET-CT can predict survival outcomes or not in T-ALL/LBL patients remains unclear. 47 adult patients of T-ALL/LBL were retrospectively reviewed. Interim PET-CT was done after induction therapy and evaluated according to the International Harmonization Project criteria. After induction therapy, interim PET-CT was positive in 19 patients (40.4%). After a median follow up time of 34 months, the 2-year and 3-year progression free survival (PFS) rate were 39% and 30%, respectively, and the 2-year and 3-year overall survival (OS) rate were 54% and 45%, respectively. Using Kaplan-Meier survival analysis, it was found that interim PET-CT positivity correlated with significantly inferior PFS and OS (2-year PFS rate for patients with positive or negative interim PET were 21.1% or 56.0%, respectively, p = 0.002; 2-year OS rate for patients with positive or negative interim PET were 31.6% or 63.7%, respectively, p = 0.010). However, there was no significant relationship between PFS, OS and bone marrow infiltration, lactate dehydrogenase level, and stages (p > 0.05). Interim PET-CT may predict PFS and OS in adult patients of T-ALL/LBL, which needs to be validated in prospective clinical trials. The optimal criteria for interim PET-CT evaluation and risk-adapted treatment strategy determined by interim PET-CT should be investigated in future clinical practice. Impact Journals LLC 2017-07-26 /pmc/articles/PMC5716796/ /pubmed/29228756 http://dx.doi.org/10.18632/oncotarget.19572 Text en Copyright: © 2017 Wang et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Clinical Research Paper
Wang, Liang
Wang, Jing-Hua
Bi, Xi-Wen
Chen, Xiao-Qin
Lu, Yue
Xia, Zhong-Jun
Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients
title Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients
title_full Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients
title_fullStr Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients
title_full_unstemmed Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients
title_short Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients
title_sort interim pet-ct may predict pfs and os in t-all/lbl adult patients
topic Clinical Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716796/
https://www.ncbi.nlm.nih.gov/pubmed/29228756
http://dx.doi.org/10.18632/oncotarget.19572
work_keys_str_mv AT wangliang interimpetctmaypredictpfsandosintalllbladultpatients
AT wangjinghua interimpetctmaypredictpfsandosintalllbladultpatients
AT bixiwen interimpetctmaypredictpfsandosintalllbladultpatients
AT chenxiaoqin interimpetctmaypredictpfsandosintalllbladultpatients
AT luyue interimpetctmaypredictpfsandosintalllbladultpatients
AT xiazhongjun interimpetctmaypredictpfsandosintalllbladultpatients